- Home
- ACB vs SLS Comparison
ACB vs SLS Comparison
Compare ACB & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACB | SLS |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.1M | 208.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ACB | SLS |
|---|---|---|
| Price | $4.06 | $4.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 1.1M | ★ 10.2M |
| Earning Date | 02-04-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $263,570,704.00 | N/A |
| Revenue This Year | $11.82 | N/A |
| Revenue Next Year | $8.58 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23.89 | N/A |
| 52 Week Low | $3.42 | $0.95 |
| 52 Week High | $6.91 | $5.18 |
Technical Indicators
Market Signals| Indicator | ACB | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 40.91 | 57.33 |
| Support Level | $3.88 | $3.66 |
| Resistance Level | $4.47 | $4.67 |
| Average True Range (ATR) | 0.14 | 0.42 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 29.75 | 44.49 |
Price Performance
Historical ComparisonAbout ACB Aurora Cannabis Inc.
Aurora Cannabis Inc headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company operates in Canada, it has expanded internationally through medical cannabis exporting agreements. The company opertes in Canada, Europe, Australia, and Others, with majority revenue from Canada.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.